Presentation Four-Step Protocol for Disparities in STEMI Careand Outcomes in Women May 07, 2018 REGISTER for free or LOG IN to view this content Coronary ACS/AMI Factoid STEMI Up Next Presentation Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial Presenter: Michelle L. O’Donoghue May 07, 2018 More slides + Presentation LPA variants, risk of coronary disease, and estimated clinical benefit of lipoprotein(a) lowering therapies: a Mendelian randomization analysis Presenter: Brian A. Ference May 07, 2018 Presentation 12-Month Results From First-in-Human Randomized Study of Ranger DCB for Femoropopliteal Treatment May 08, 2018 We Recommend
Presentation Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial Presenter: Michelle L. O’Donoghue May 07, 2018
Presentation LPA variants, risk of coronary disease, and estimated clinical benefit of lipoprotein(a) lowering therapies: a Mendelian randomization analysis Presenter: Brian A. Ference May 07, 2018
Presentation 12-Month Results From First-in-Human Randomized Study of Ranger DCB for Femoropopliteal Treatment May 08, 2018